172 related articles for article (PubMed ID: 21093020)
1. Cancer in patients with rheumatic diseases exposed to TNF antagonists.
Carmona L; Abasolo L; Descalzo MA; Pérez-Zafrilla B; Sellas A; de Abajo F; Gomez-Reino JJ; ;
Semin Arthritis Rheum; 2011 Aug; 41(1):71-80. PubMed ID: 21093020
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
Carmona L; Gómez-Reino JJ; Rodríguez-Valverde V; Montero D; Pascual-Gómez E; Mola EM; Carreño L; Figueroa M;
Arthritis Rheum; 2005 Jun; 52(6):1766-72. PubMed ID: 15934089
[TBL] [Abstract][Full Text] [Related]
3. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.
Gómez-Reino JJ; Carmona L; Angel Descalzo M;
Arthritis Rheum; 2007 Jun; 57(5):756-61. PubMed ID: 17530674
[TBL] [Abstract][Full Text] [Related]
4. Non-typhi Salmonella infection in patients with rheumatic diseases on TNF-alpha antagonist therapy.
Peña-Sagredo JL; Fariñas MC; Perez-Zafrilla B; Cruz-Valenciano A; Crespo M; Joven-Ibañez B; Riera E; Manero-Ruiz FJ; Chalmeta I; Hernández MV; Rodríguez-Gómez M; Maíz O; López R; Cobo T; Pita J; Carmona L; Gonzalez-Gay MA;
Clin Exp Rheumatol; 2009; 27(6):920-5. PubMed ID: 20149306
[TBL] [Abstract][Full Text] [Related]
5. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.
Raaschou P; Simard JF; Neovius M; Askling J;
Arthritis Rheum; 2011 Jul; 63(7):1812-22. PubMed ID: 21305513
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases.
Hernández MV; Sanmartí R; Cañete JD; Descalzo MA; Alsina M; Carmona L; Gomez-Reino JJ;
Arthritis Care Res (Hoboken); 2013 Dec; 65(12):2024-31. PubMed ID: 23926075
[TBL] [Abstract][Full Text] [Related]
7. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists.
Carmona L; Descalzo MA; Perez-Pampin E; Ruiz-Montesinos D; Erra A; Cobo T; Gómez-Reino JJ;
Ann Rheum Dis; 2007 Jul; 66(7):880-5. PubMed ID: 17324968
[TBL] [Abstract][Full Text] [Related]
8. Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0.
Carmona L; Descalzo MA; Ruiz-Montesinos D; Manero-Ruiz FJ; Perez-Pampin E; Gomez-Reino JJ;
Rheumatology (Oxford); 2011 Jan; 50(1):85-92. PubMed ID: 20601654
[TBL] [Abstract][Full Text] [Related]
9. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.
Askling J; Fored CM; Baecklund E; Brandt L; Backlin C; Ekbom A; Sundström C; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L; Feltelius N
Ann Rheum Dis; 2005 Oct; 64(10):1414-20. PubMed ID: 15843454
[TBL] [Abstract][Full Text] [Related]
10. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.
Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Romanus V; Klareskog L; Feltelius N
Arthritis Rheum; 2005 Jul; 52(7):1986-92. PubMed ID: 15986370
[TBL] [Abstract][Full Text] [Related]
11. Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis.
Ljung L; Simard JF; Jacobsson L; Rantapää-Dahlqvist S; Askling J;
Arthritis Rheum; 2012 Jan; 64(1):42-52. PubMed ID: 21898355
[TBL] [Abstract][Full Text] [Related]
12. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
Wolfe F; Michaud K
Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
[TBL] [Abstract][Full Text] [Related]
13. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.
Gómez-Reino JJ; Carmona L; Valverde VR; Mola EM; Montero MD;
Arthritis Rheum; 2003 Aug; 48(8):2122-7. PubMed ID: 12905464
[TBL] [Abstract][Full Text] [Related]
14. Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0.
Gómez-Reino JJ; Rodríguez-Lozano C; Campos-Fernández C; Montoro M; Descalzo MÁ; Carmona L;
Ann Rheum Dis; 2012 Mar; 71(3):382-5. PubMed ID: 21998116
[TBL] [Abstract][Full Text] [Related]
15. Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry.
Busquets N; Tomero E; Descalzo MÁ; Ponce A; Ortiz-Santamaría V; Surís X; Carmona L; Gómez-Reino JJ;
Rheumatology (Oxford); 2011 Nov; 50(11):1999-2004. PubMed ID: 21856725
[TBL] [Abstract][Full Text] [Related]
16. Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry.
Pallavicini FB; Caporali R; Sarzi-Puttini P; Atzeni F; Bazzani C; Gorla R; Marchesoni A; Favalli EG; Montecucco C
Autoimmun Rev; 2010 Jan; 9(3):175-80. PubMed ID: 19647103
[TBL] [Abstract][Full Text] [Related]
17. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC
J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor-α blockade, cardiovascular outcomes, and survival in rheumatoid arthritis.
Al-Aly Z; Pan H; Zeringue A; Xian H; McDonald JR; El-Achkar TM; Eisen S
Transl Res; 2011 Jan; 157(1):10-8. PubMed ID: 21146146
[TBL] [Abstract][Full Text] [Related]
19. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review.
Cruz Fernández-Espartero M; Pérez-Zafrilla B; Naranjo A; Esteban C; Ortiz AM; Gómez-Reino JJ; Carmona L;
Semin Arthritis Rheum; 2011 Dec; 41(3):524-33. PubMed ID: 22152489
[TBL] [Abstract][Full Text] [Related]
20. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists.
Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L
Ann Rheum Dis; 2005 Oct; 64(10):1421-6. PubMed ID: 15829572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]